Monday, 01 March 2021

Baxter announces collaboration with Laboratoire Aguettant

06 April 2015 | News | By BioSpectrum Bureau

Baxter announces collaboration with Laboratoire Aguettant

The collaboration allows Baxter to augment its leading PN portfolio

The collaboration allows Baxter to augment its leading PN portfolio

Baxter International and Laboratoire Aguettant has announced that they have signed an exclusive global licensing and distribution agreement for trace elements, which are essential micronutrients used in parenteral nutrition (PN) therapy. The collaboration allows Baxter to augment its leading PN portfolio, currently available in more than 90 countries, with essential trace elements.

"Providing access to a comprehensive range of parenteral nutrition products is critical for patients who rely on IV administration of these nutrients," said Mr Brik Eyre, president of Baxter's Hospital Products business. He added, "This agreement complements Baxter's existing parenteral nutrition portfolio and provides clinicians with options to meet the individual needs of both chronic and critically ill parenteral nutrition patients."

The agreement includes NUTRYELT concentrate solution for infusion (a multi-trace element product) for adults, and SELENIUM and ZINC (single-trace element products). NUTRYELT contains nine essential trace elements consistent with the most recent European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines for trace elements.

NUTRYELT was approved in France, Germany, Poland and the United Kingdom in 2014, and is pending approval in 15 additional European countries. SELENIUM and ZINC are two of the most commonly used stand-alone trace elements. The companies will work together to pursue even broader global regulatory approvals for these products, including in the United States. Aguettant will retain ownership of the worldwide rights of the trace elements, and will directly market these products in France.

"Aguettant and Baxter have previously partnered to provide trace elements in Europe, and during times of product shortages in the United States. This agreement significantly expands the internationalization of Aguettant. It brings together our companies' unique expertise, channels to market and technologies that will allow us to reach more patients with these essential nutritional products," said Mr Eric Rougemond, CEO of Laboratoire Aguettant SAS.




× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls